RecruitingPhase 1NCT06500793

Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)

Studying NLRP3-associated autoinflammatory disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ensysce Biosciences
Principal Investigator
Jeffrey Levy, MD, PhD
Medical Director, Quotient Sciences
Intervention
PF614 capsule(drug)
Enrollment
30 target
Eligibility
18-55 years · All sexes
Timeline
20242026

Study locations (1)

Collaborators

Quotient Sciences

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06500793 on ClinicalTrials.gov

Other trials for NLRP3-associated autoinflammatory disease

Additional recruiting or active studies for the same condition.

See all trials for NLRP3-associated autoinflammatory disease

← Back to all trials